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ABSTRACT
Objective: To evaluate the efficacy of adalimumab in the
healing of draining fistulas in patients with active Crohn’s
disease (CD).
Design: A phase III, multicentre, randomised, double-
blind, placebo controlled study with an open-label
extension was conducted in 92 sites.
Patients: A subgroup of adults with moderate to severely
active CD (CD activity index 220–450) for >4 months
who had draining fistulas at baseline.
Interventions: All patients received initial open-label
adalimumab induction therapy (80 mg/40 mg at weeks 0/2).
At week 4, all patients were randomly assigned to receive
double-blind placeboor adalimumab40 mg every other week
or weekly to week 56 (irrespective of fistula status). Patients
completing week 56 of therapy were then eligible to enroll in
an open-label extension.
Main Outcome Measures: Complete fistula healing/
closure (assessed at every visit) was defined as no
drainage, either spontaneous or with gentle compression.
Results: Of 854 patients enrolled, 117 had draining
fistulas at both screening and baseline (70 randomly
assigned to adalimumab and 47 to placebo). The mean
number of draining fistulas per day was significantly
decreased in adalimumab-treated patients compared with
placebo-treated patients during the double-blind treat-
ment period. Of all patients with healed fistulas at week
56 (both adalimumab and placebo groups), 90% (28/31)
maintained healing following 1 year of open-label
adalimumab therapy (observed analysis).
Conclusions: In patients with active CD, adalimumab
therapy was more effective than placebo for inducing fistula
healing. Complete fistula healing was sustained for up to
2 years by most patients in an open-label extension trial.
ClinicalTrials.gov Identifier: NCT00077779 and
NCT00195715.
Fistulising disease complicates Crohn’s disease
(CD) in up to 40% of patients.
1–3 Fistulas rarely
heal spontaneously and usually require medical
therapy or surgery.
1 Antibiotics and immunosup-
pressive agents have been widely used for treat-
ment, although their efficacy for the sustained
closure of fistulas has not been proved.
1 Tumour
necrosis factor (TNF) antagonists specifically
target the elevated concentrations of TNF that
contribute to the pathological inflammation in CD
and represent a significant therapeutic advance in
the treatment of patients with CD. Infliximab, a
chimeric monoclonal antibody to TNF, has been
shown to be effective for the treatment of fistulas.
4
In patients with an initial response to infliximab
induction therapy, there is an increased likelihood
of sustained response if infusions are continued
every 8 weeks.
5 Clinical trials have demonstrated
that adalimumab, a self-injected fully human
monoclonal antibody to TNF, is effective for the
induction and maintenance of remission in
patients with moderate to severe CD.
6–10 In
addition, in patients with CD who have lost
response to or have become intolerant of inflix-
imab, adalimumab has been demonstrated to be
safe and efficacious in regaining a medical
response.
11
The Crohn’s Trial of the Fully Human Antibody
Adalimumab for Remission Maintenance
(CHARM)
6 was a large, phase III, randomised,
double-blind, placebo controlled, 56-week study of
patients with moderate to severe CD who may or
may not have received TNF antagonist therapy
previously. The primary objective was to assess the
benefit of two adalimumab dosing regimens in
maintaining clinical remission at 26 and 56 weeks.
Among patients who responded to adalimumab,
both dosing regimens (40 mg of adalimumab every
other week (eow) and weekly) were statistically
significantly more effective than placebo in main-
taining remission to 56 weeks. Overall efficacy in
fistula closure was also assessed, with significant
effects of adalimumab therapy on fistula closure
observed at both weeks 26 and 56.
6 The objectives
of the present analysis of patients with fistulas in
CHARM were as follows: (1) to describe fully the
demographics, disease characteristics and safety
outcome of these patients with fistulas; (2) to
describe a new statistical approach that was
developed to provide a more accurate and long-
itudinal approximation of fistula burden than was
possible with previous approaches by calculating
the number of draining fistulas per day for each
individual patient and (3) to evaluate the 2-year
maintenance of fistula healing during treatment
with adalimumab in an open-label extension study
(called the ADHERE trial—Additional Long-Term
Dosing with HUMIRA to Evaluate Sustained
Remission and Efficacy in Crohn’s disease).
METHODS
Study design
Detailed CHARM study methodology was
reported previously.
6 CHARM was a 56-week,
multicentre, randomised, double-blind, placebo
controlled trial with a 4-week open-label induction
period. Patients successfully completing CHARM
could enroll in an open-label extension study
(ADHERE) (fig 1). At baseline, patients received
open-label adalimumab 80 mg subcutaneously
followed by 40 mg at week 2. At week 4, all
patients still enrolled were stratified by whether or
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decrease in the Crohn’s disease activity index (CDAI) of >70
points compared with baseline). Patients were then randomly
assigned within each strata in a 1 : 1 : 1 ratio to one of three
treatment groups: adalimumab 40 mg eow, adalimumab 40 mg
weekly, or placebo.
6
At or after week 12, a patient with a flare or non-response
could be switched to open-label treatment with 40 mg of
adalimumab eow, which could be increased to 40 mg weekly if
needed. Continued non-response on open-label adalimumab
40 mg weekly resulted in withdrawal from the study. A flare
was defined as a recurrence of very active disease (CDAI
increase >70 points from week 4 and a CDAI .220). Non-
response was defined as failure to achieve 70-point response at
any visit at or after week 12.
All patients who successfully completed CHARM could enter
the extension study (ADHERE). Patients who completed
CHARM on placebo therapy received open-label adalimumab
eow. Patients who had switched to open-label adalimumab eow
or weekly continued on those regimens, and patients could
switch from eow to weekly dosing in the event of flares or non-
response. Of note, patients could not decrease their dosing
intervals back to eow once they began receiving weekly dosing
in either study. In addition, patient visits in ADHERE (weeks 0,
2, 4, 8 and 12 and then every 12 weeks) were much less frequent
than in CHARM (every 2 weeks to week 8, every 4 weeks to
week 20, every 6 weeks to week 32 and then every 8 weeks to
study end in the original CHARM controlled trial).
Patients
Patients all had moderately to severely active CD, defined as a
CDAI score between 220 and 450.
12 Enrollment with a history of
infliximab treatment was permissible only if infliximab had
been discontinued at least 12 weeks before the screening visit
and the patient had experienced an initial response to the agent
(as judged by the investigator). Demographic and baseline
disease severity data, concomitant medication use at baseline,
previous history of TNF antagonist use and smoking history
were collected for the entire population of patients in CHARM,
but only patients with draining fistulas at screening and
baseline are included in the subgroup analyses reported here.
Baseline fistula data, that is the number of fistulas and their
location, were noted and recorded.
Efficacy assessments
The primary endpoint in CHARM was clinical remission and
the study was statistically powered based on predicted
remission rates. Fistula healing and the mean number of
draining fistulas per day were predetermined secondary end-
points in CHARM; however, the study was not powered for
secondary endpoints. Patients classified as having fistulas were
only those with draining fistulas at both screening and at
baseline of CHARM. Fistulas were assessed for spontaneous
drainage or drainage with gentle compression at each study
visit. Complete fistula healing was defined as the absence of
drainage under both these circumstances.
In addition to these standard assessments of fistula closure at
set time points, a new, prespecified statistical method was used
to determine the number of draining fistulas per day. Fistula
closure rates for patients with fistulas at baseline were also
stratified by baseline immunosuppressant use (yes or no),
baseline CD-related antibiotic use (yes or no) and previous
history of use of any TNF antagonist (yes or no), as well as the
reason for the discontinuation of the previous TNF antagonist
(loss of response, adverse reaction, both).
Two post-hoc analyses were conducted to assess the
sustained effect of adalimumab on fistula efficacy to 2 years
of treatment (week 60 of ADHERE). The first analysis evaluated
long-term fistula healing to 2 years of adalimumab therapy. The
second analysis evaluated the maintenance of fistula healing in
all patients with healed fistulas at the end of CHARM. In the
primary fistula analysis specified in the statistical analysis plan,
complete fistula healing (also referred to as complete fistula
closure) was defined as the absence of draining fistulas for at
least the last two post-baseline evaluations on or before the
study visit in CHARM. Because of the reduced frequency of
visits in ADHERE, fistula healing was defined as occurring at
the time point of the visit, rather than for at least two
Figure 1 Study design. Flare was defined as a recurrence of very active disease (Crohn’s disease activity index (CDAI) increase >70 points after
week 4 and a CDAI .220). Non-response was defined as a failure to achieve 70-point response at any visit on or after week 12. *Option to adjust
dosage to weekly for flare/non-response. ADHERE, Additional Long-Term Dosing with HUMIRA to Evaluate Sustained Remission and Efficacy in Crohn’s
disease; CHARM, Crohn’s Trial of the Fully Human Antibody Adalimumab for Remission Maintenance; eow, every other week.
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Gut 2009;58:940–948. doi:10.1136/gut.2008.159251 941Figure 2 Patient disposition. (A) Patient disposition to week 56 of the Crohn’s Trial of the Fully Human Antibody Adalimumab for Remission
Maintenance (CHARM). Randomly assigned responders achieved a 70-point or greater decrease in the Crohn’s disease activity index score at week 4 in
CHARM. (B) Patient disposition for sustained fistula response over 2 years of adalimumab therapy in patients randomly assigned to adalimumab in
CHARM and who enrolled in the Additional Long-Term Dosing with HUMIRA to Evaluate Sustained Remission and Efficacy in Crohn’s disease (ADHERE)
study (analysis 1). (C) Patient disposition for sustained fistula response in all patients with healed fistulas at the end of CHARM (includes adalimumab
and placebo-treated patients who entered ADHERE) (analysis 2). *Denominator for non-responder imputation (NRI) analyses. {Denominator for
observed-case analysis at the end of CHARM. {Denominator for observed-case analysis to 2 years of therapy. eow, every other week.
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fistula analysis. For consistency, this definition of healing at a
single time point for the 2-year analysis was used starting from
the baseline of CHARM.
Safety assessments
For evaluation of safety in the subset of patients with fistulas at
baseline, serious adverse events and other adverse events of
interest were collected throughout the study and its extension.
Statistical analysis
Fistula results were evaluated for all randomly assigned patients
with draining fistulas at both baseline and screening visits. The
prespecified statistical analysis plan stipulated that fistula data
from both adalimumab treatment groups (weekly and eow) be
combined (owing to the anticipated small sample sizes of patients
with fistulas) and compared with the placebo group. All analyses
were based on two-sided tests with a = 0.05. Continuous
variables were compared using analyses of covariance adjusted
for baseline values and discrete variables were compared using x
2
tests.
To calculate the draining fistulas per day, a new statistical
approach was developed a priori to express the total fistula
burden of each individual patient over the course of their
blinded participation in CHARM. Starting at week 0 and ending
at week 56 (or study discontinuation), the number of draining
fistulas at each pair of consecutive evaluations was averaged and
multiplied by the elapsed days between the evaluations to
obtain the number of draining fistula days. The total number of
draining fistula days was summed from week 0 to week 56 (or
study discontinuation) and divided by the total days in the
study to obtain the average number of draining fistulas per day.
The difference between each blinded adalimumab group and the
placebo group was assessed with least-squares means from the
analysis of variance with treatment as the only factor. Of note,
the number of study days excluded days after discontinuation
of double-blind study drug. Similarly, draining fistulas observed
after study discontinuation or after the discontinuation of
double-blind treatment were excluded from the analysis. If a
missing evaluation had non-missing double-blind evaluations
Table 1 Baseline demographics and clinical characteristics
Characteristics
All patients
(n = 854)
Patients with fistulas at baseline
Placebo
(n = 47)
Adalimumab
(n = 70)
All patients
with fistulas
(n = 117)
Male, no (%) 326 (38.2) 15 (31.9) 34 (48.6) 49 (41.9)
Age in years, mean (SD) 37.1 (11.9) 36.5 (10.1) 35.9 (12.2) 36.1 (11.4)
Baseline CDAI score, mean (SD) 313.1 (62.0) 308.0 (59.3) 318.4 (55.8) 314.3 (57.2)
CRP (mg/dl)
Mean (SD) 2.3 (3.4) 3.6 (4.7) 2.8 (3.0) 3.1 (3.8)
Median (range) 0.9 (0.02–35.0) 2.3 (0.12–28.7) 1.8 (0.06–12.3) 1.9 (0.06–28.7)
CRP concentration >1.0 mg/dl (10 mg/l), n (%) 407 (47.7) 32 (68.1) 42 (60.0) 74 (63.2)
Previous TNF antagonist exposure, n (%) 424 (49.6) 31 (66.0) 41 (58.6) 72 (61.5)
Concomitant medication, n (%)
Any glucocorticoid* 376 (44.0) 20 (42.6) 29 (41.4) 49 (41.9)
Prednisone 244 (28.6) 14 (29.8) 18 (25.7) 32 (27.4)
Budesonide 100 (11.7) 9 (19.1) 2 (2.9) 11 (9.4)
Any immunosuppressive agent 399 (46.7) 26 (55.3) 31 (44.3) 57 (48.7)
Azathioprine 275 (32.2) 21 (44.7) 24 (34.3) 45 (38.5)
6-Mercaptopurine 81 (9.5) 4 (8.5) 3 (4.3) 7 (6.0)
Methotrexate 90 (10.5) 3 (6.4) 7 (10.0) 10 (8.5)
5-Aminosalicylates{ 334 (39.1) 13 (27.7) 24 (34.3) 37 (31.6)
Current smoker, no (%) 303 (35.5) 18 (38.3) 20 (28.6) 38 (32.5)
*Includes betamethasone, budesonide, dexamethasone, deflazacort, cortisone, cloprednol, fluocortolone, glucocorticoids,
hydrocortisone, methylprednisolone, prednisolone, prednisone, paramethasone and prednylidene. {Aminosalicylic acid, balsalazide,
mesalazine, olsalazine, sulfasalazine. CDAI, Crohn’s disease activity index; CRP, C-reactive protein; TNF, tumour necrosis factor.
Table 2 Baseline fistula data
Characteristic Placebo (n = 47)
Adalimumab 40 mg
eow (n = 30)
Adalimumab 40 mg
weekly (n = 40)
Draining cutaneous fistulas,* no (%)
One 30 (63.8) 19 (63.3) 23 (57.5)
Two 7 (14.9) 6 (20.0) 7 (17.5)
Three 6 (12.8) 1 (3.3) 5 (12.5)
Four 4 (8.5) 4 (13.3) 5 (12.5)
Perianal fistulas,{ no (%)
One 29 (64.4) 19 (63.3) 21 (55.3)
Two 7 (15.6) 6 (20.0) 7 (18.4)
Three 6 (13.3) 1 (3.3) 5 (13.2)
Four 3 (6.7) 4 (13.3) 5 (13.2)
*Draining cutaneous fistulas includes perianal fistulas (n = 113) and abdominal fistulas (n = 4). {n = 45 for placebo; n = 30
for 40 mg adalimumab eow; n = 38 for 40 mg adalimumab weekly. eow, every other week.
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evaluations was used to estimate the missing evaluation. This
analysis was conducted for all randomly assigned patients and
randomly assigned responders (defined as patients who achieved
>70 point decreases in CDAI scores at week 4 in CHARM).
The first analysis of long-term fistula healing to 2 years of
adalimumab therapy included only those patients who were
randomly assigned to adalimumab in CHARM and who entered
ADHERE (analysis 1). Data were summarised at each visit using
an observed-case analysis and non-responder imputation (NRI).
In the second analysis of maintenance of fistula healing and
response, all patients with healed fistulas at the end of CHARM
(ie, both adalimumab and placebo-treated patients) were
followed into ADHERE (analysis 2). In this analysis, data were
summarised at weeks 24 and 60 of ADHERE (representing
approximately 18 months and 2 years of therapy, respectively)
using both observed and NRI analyses. With NRI analyses, the
assumption is that patients with missing data or those who had
left the trial were failures for the endpoint in question (ie, fistula
healing).
RESULTS
Patients
The demographics and patient disposition for the overall
CHARM patient population were previously described.
6 Of
the 778 patients randomly assigned at week 4 to receive placebo
(n = 261), adalimumab 40 mg eow (n = 260) or adalimumab
40 mg weekly (n = 257), there was a total of 117 patients with
draining fistulas at screening and baseline (placebo, n = 47;
40 mg eow, n = 30; and 40 mg weekly, n = 40; fig 2A).
Figs 2B and C display the numbers of patients included in the
long-term fistula efficacy analyses (to 2 years from CHARM
baseline) and the reasons for exclusion from analysis. Baseline
characteristics are presented in table 1.
Baseline characteristics of the patients with draining fistulas
at screening and baseline were similar compared with the
remainder of the patients, with the exception of numerically
greater C-reactive protein concentrations and a previous history
of TNF antagonist exposure in the patients with fistulising
disease. Baseline fistula data are presented in table 2.
Efficacy
Adalimumab therapy was associated with progressive increases
in fistula closure over time, with separation in the rates of
complete closure between placebo and adalimumab groups
evident as early as 2 weeks after randomisation. Statistically
significant differences in fistula closure between placebo and
adalimumab were first observed at 16 weeks (fig 3). Baseline
immunosuppressant or CD-related antibiotic use had no
apparent effect on the rates of fistula closure in patients
receiving adalimumab or placebo at weeks 26 or 56, although
the numbers of patients in each group were relatively small
(table 3). In addition, whether patients were naive to or
experienced with TNF antagonists before receiving adalimumab
did not appear to effect fistula healing (data not shown).
The new statistical methodology for determining fistula
burden was used to calculate the number of draining fistulas per
day during the double-blind period. For all randomly assigned
patients and also all randomly assigned responder patients
(those with week 4 CDAI decreases >70 points vs baseline),
there were significant decreases in the mean number of draining
fistulas per day among adalimumab-treated patients compared
with placebo-treated patients during the double-blind treat-
ment period (fig 4). For all randomly assigned patients, the
mean number of draining fistulas per day was 1.34 for placebo
compared with a mean of 0.88 for the combined adalimumab
groups (p=0.002). Results were similar for the randomly
assigned responders (mean 1.15 for placebo, mean 0.76 for
adalimumab groups combined, p=0.043). The effect of
adalimumab on the number of draining fistulas in each
subgroup (based on immunosuppressant, antibiotic, or previous
TNF antagonist exposure) was similar to that observed for the
overall placebo and adalimumab groups (data not shown).
Fistula healing over time for all patients with fistulas who
were randomly assigned to adalimumab is provided in table 4
(observed analysis). Of the adalimumab-treated patients with
fistulas at baseline (n = 70) approximately 60% (22/37) had
healed fistulas after 2 years of therapy (table 4). Long-term
fistula healing over time using NRI analysis is provided in
Figure 3 Percentage of patients with fistulas at baseline (adalimumab
every other week (eow) and weekly combined, n = 70; placebo,
n = 47) who had complete fistula healing over time in the Crohn’s Trial
of the Fully Human Antibody Adalimumab for Remission Maintenance
(CHARM; non-responder imputation analysis). *p,0.05 for combined
adalimumab groups (40 eow and 40 mg weekly) compared with placebo
for the intention-to-treat population. Fistula efficacy defined as no
draining fistulas at the last two consecutive post-baseline evaluations in
the double-blind period before and on that visit.
Table 3 Percentage of patients with no draining fistulas at weeks 26
and 56 for all patients with fistulas at baseline (n = 117) stratified by
baseline concomitant therapies
Subgroup
No draining fistulas*
Week 26
% of patients
Week 56
% of patients
No baseline immunosuppressant use
Placebo (n = 21) 19 19
Both adalimumab groups (n = 39) 33 (p=0.369) 36 (p=0.241)
Baseline immunosuppressant use
Placebo (n = 26) 8 8
Both adalimumab groups (n = 31) 26 (p=0.092) 29 (p=0.051)
No baseline CD-related antibiotic use
Placebo (n = 28) 14 14
Both adalimumab groups (n = 44) 32 (p=0.162) 36 (p=0.059)
Baseline CD-related antibiotic use
Placebo (n = 19) 11 11
Both adalimumab groups (n = 26) 27 (p=0.264) 27 (p=0.264)
*Patients who had no draining fistulas at the last two post-baseline evaluations in the
double-blind period on or before the week 26 or week 56 visits were classified as no;
otherwise, patients were classified as yes. p Values from x
2 tests comparing both
adalimumab groups combined versus placebo. CD, Crohn’s disease.
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managed according to inflammatory activity and therapy
dosage changes were not predicated on fistula response (fistula
is part of CDAI, which is an inflammatory scale assessing
disease activity), NRI is a very conservative approach to the data
analysis.
Long-term maintenance of fistula healing rates for patients
with healed fistulas at the end of CHARM (n = 40) are
provided in fig 5. Of these patients, 90% (28/31) maintained
healed fistulas after one additional year of treatment in
ADHERE (2 years from CHARM baseline, observed analysis).
In the NRI analysis, 75% of patients maintained healing to
2 years of therapy.
Safety
Adalimumab was well tolerated for up to 56 weeks of treatment
in patients with fistulas at baseline (table 6), similar to the
findings for all randomly assigned patients reported by
Colombel et al.
6 Safety data in the fistula cohort to 2 years
from CHARM baseline are presented in table 7. With respect to
the serious events of abscess, eight events were reported in the
70 adalimumab-treated patients in the fistula cohort who
received 2 years of therapy; one additional event was reported
in a patient originally randomly assigned to placebo.
DISCUSSION
These data extend and define the beneficial effect of adalimu-
mab on fistula healing in patients with CD and provide the first
long-term fistula healing results with an anti-TNF therapy. This
study also introduces and utilises a new methodology for
evaluating the effect of treatment in patients with fistulising
disease. The demographic characteristics of patients with
fistulising disease did not differ substantially from the overall
study population in CHARM. In this subgroup of patients
whose CD was often difficult to manage because of fistulising
disease, adalimumab still demonstrated a consistent and
significant reduction of draining fistulas when compared with
placebo in patients with moderate to severe CD. The effect of
adalimumab on fistula closure was durable, as demonstrated by
three-quarters of the adalimumab-treated patients (NRI; 90%
with observed analyses) who had healed fistulas at the end of
CHARM maintaining closure following an additional year of
open-label therapy.
The efficacy of adalimumab was consistent in subgroups of
patients with fistulas who were or were not receiving
concomitant therapy with immunosuppressive agents or anti-
biotics, as well as in patients naive to and experienced with TNF
antagonist therapy. However, caution should be exercised in
interpreting these analyses as a result of the small numbers of
patients in each subgroup.
In addition to standard assessments of fistula closure at set
time points, a new, prespecified statistical method was used to
determine the number of draining fistulas per day. Specific
examples of the statistical analysis are depicted in fig 6. With
the definition of complete fistula healing used in this analysis,
hypothetical patient 1 (fig 6A) would have been assessed as not
having successful closure of fistulas at either individual time
point (week 26 or week 56), whereas hypothetical patient 2
(fig 6B) would have been assessed as having successful closure at
week 56. With the new method of measuring fistulas per day
reported here, it becomes evident that hypothetical patient 1
Figure 4 Mean number of draining fistulas per day during double-blind
period. *Statistical analyses were not performed on individual
adalimumab groups, per prespecified statistical plan. {Intention-to-treat
population of patients with draining fistulas at screening and baseline
visits. {Randomised responder population (>70 point decrease in
Crohn’s disease activity index score at week 4 in the Crohn’s Trial of the
Fully Human Antibody Adalimumab for Remission Maintenance) of
patients with draining fistulas at screening and baseline visits.
eow, every other week; n, number of patients with fistulas at baseline.
Table 4 Long-term efficacy of fistula healing with
adalimumab to 2 years from CHARM baseline: observed
analysis*
Time point
Observed analysis
n/No (%)
6 Months in CHARM 32/58 (55)
1 Year in CHARM 29/50 (58)
24 Weeks in ADHERE 25/42 (60)
36 Weeks in ADHERE 26/40 (65)
48 Weeks in ADHERE 23/37 (62)
60 Weeks in ADHERE{ 22/37 (59)
*Includes all adalimumab-treated patients with fistulas at the
baseline of the Crohn’s Trial of the Fully Human Antibody
Adalimumab for Remission Maintenance (CHARM) remaining in
CHARM or the Additional Long-Term Dosing with HUMIRA to
Evaluate Sustained Remission and Efficacy in Crohn’s disease study
(ADHERE; open-label extension) at the time points specified. Fistula
efficacy defined as complete healing/closure of draining fistulas at
time point since baseline of CHARM. {60 weeks in ADHERE
represents approximately 2 years of adalimumab therapy.
Table 5 Long-term efficacy of fistula healing with
adalimumab to 2 years from CHARM baseline: NRI
analysis*
Time point
NRI (n = 70)
No (%)
6 Months in CHARM 32 (46)
1 Year in CHARM 29 (41)
24 Weeks in ADHERE 25 (36)
36 Weeks in ADHERE 26 (37)
48 Weeks in ADHERE 23 (33)
60 Weeks in ADHERE{ 22 (31)
*Includes all adalimumab-treated patients (every other week and
weekly groups combined, N = 70) with fistulas at baseline of the
Crohn’s Trial of the Fully Human Antibody Adalimumab for
Remission Maintenance (CHARM). Fistula efficacy defined as
complete healing/closure of draining fistulas at time point since
baseline of CHARM. {60 weeks in the Additional Long-Term Dosing
with HUMIRA to Evaluate Sustained Remission and Efficacy in
Crohn’s disease (ADHERE) study represents approximately 2 years
of adalimumab therapy. NRI, non-responder imputation.
Inflammatory bowel disease
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did hypothetical patient 2. Evaluation of ‘‘fistulas per day’’ more
accurately reflects disease activity over the entire study period,
instead of focusing on fistula counts at single points in time as
does the definition of fistula healing. By providing a longitudinal
perspective, this new methodology may yield a more accurate
picture of the total fistula experience of each individual patient
over the full course of participation in the study. This analysis,
which facilitates the comparison of subgroups of patients
within an individual study, was prespecified in the statistical
analysis plan for the CHARM study. One limitation of this
method is that between the visits, the numbers of draining
fistulas on each day are assumed to remain the same and
approximate the average number of draining fistulas observed at
each visit. This assumption requires validation in appropriately
constructed clinical trials.
Infliximab is the only other TNF antagonist shown to be
effective in inducing and maintaining fistula closure.
45In the
ACCENT II study (Crohn’s Disease Clinical Study Evaluating
Infliximab in a New Long-Term Treatment Regimen II), 36% of
patients who had responded to induction therapy and received
maintenance infliximab therapy maintained complete fistula
closure compared with 19% of patients receiving placebo
(p=0.009).
5 In ACCENT II, patients were included based on
a minimal duration of fistula activity; only patients who
responded to initial induction therapy were included in the
analysis of maintenance efficacy.
5 In CHARM, patients were
included based on the overall activity of their CD and not on
fistula activity, and all patients with fistulas were included in
the analysis irrespective of initial response to adalimumab.
Despite these differences, the fistula closure rates from
ACCENT II at week 54 are generally comparable to the fistula
closure rates observed with adalimumab treatment at week 56.
In two studies of certolizumab pegol (PRECiSE 1 and 2), a
pegylated Fab9 fragment of an anti-TNF monoclonal antibody,
the effect of certolizumab on fistula closure was not statistically
significantly different compared with placebo.
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Patients with fistulas at baseline tolerated sustained adali-
mumab treatment well. The safety profile of adalimumab in
CHARM was consistent with studies of adalimumab in
rheumatological disorders and with previous studies of patients
Figure 5 Long-term maintenance of fistula healing (absence of
drainage from all fistulas, either spontaneously or upon gentle
compression) in patients with healed fistulas at the end of the Crohn’s
Trial of the fully Human Antibody Adalimumab for Remission
Maintenance (CHARM; placebo, every other week (eow) and weekly;
n = 40).*Observed analysis: two placebo-treated patients with healed
fistulas did not enter Additional Long-Term Dosing with HUMIRA to
Evaluate Sustained Remission and Efficacy in Crohn’s disease (ADHERE)
study; data on fistula outcomes were missing for four patients at
24 weeks in ADHERE and seven patients at 60 weeks in ADHERE. {Non-
responder imputation analysis: two placebo-treated patients with healed
fistulas did not enter ADHERE.
Table 6 Summary of safety in adalimumab and placebo-treated
patients with fistulas to 56 weeks in CHARM
Event
Placebo
(n = 47)
All
adalimumab
(n = 70)
No (%) No (%)
Adverse event 38 (80.9) 59 (84.3)
Serious adverse event 5 (10.6) 9 (12.9)
Adverse event leading to discontinuation of study
medication
3 (6.4) 4 (5.7)
Infectious adverse event 16 (34.0) 31 (44.3)
Serious infectious adverse event* 2 (4.3) 5 (7.1)
Abscess (all) 5 (10.6) 8 (11.4)
Malignant neoplasm 0 0
Injection-site reaction (all) 2 (4.3) 3 (4.3)
Opportunistic infection{ 1 (2.1) 0
Congestive heart failure 0 0
Demyelinating disorder 0 0
Death 0 0
*Both of the placebo-treated patients had an abdominal abscess. The serious
infectious adverse events for the five adalimumab-treated patients were a pulmonary
embolus with pneumonia (n = 1); intra-abdominal abscess (n = 1); perianal
abscess (n = 2) and scrotal abscess (n = 1). {Oral candidiasis. CHARM, Crohn’s
Trial of the fully Human Antibody Adalimumab for Remission Maintenance.
Table 7 Summary of safety in cohort of patients with fistulas to
2 years from CHARM baseline
Event
All patients
with fistula
(adalimumab
and placebo)
(n = 117)
All adalimumab
patients with
fistula (eow and
weekly combined)
(n = 70)
No (%) No (%)
Adverse event 112 (95.7) 70 (100)
Serious adverse event 33 (28.2) 22 (31.4)
Adverse event leading to discontinuation
of study medication
19 (16.2) 13 (18.6)
Infectious adverse event 76 (65.0) 53 (75.7)
Serious infectious adverse event 13 (11.1)* 10 (14.3){
Serious gastrointestinal adverse event 15 (12.8){ 13 (18.6)1
Malignant neoplasm 1 (0.9) 0
Injection-site pain 7 (6.0) 4 (5.7)
Opportunistic infection 0 0
Congestive heart failure 0 0
Demyelinating disorder 0 0
Death 0 0
*Fifteen events were reported in 13 patients: nine events of abscess (four perianal,
two abdominal, one rectal, one scrotal, one not specified), one event of clostridial
infection, one event of sepsis, one event of pneumonia, one event of tuberculosis, one
event of otitis media and one event of post-procedural infection. {Twelve events were
reported in 10 patients: eight events of abscess (three perianal, two abdominal, one
rectal, one scrotal, one not specified), one event of clostridial infection, one event of
pneumonia, one event of tuberculosis and one event of otitis media. {Seventeen
events were reported in 15 patients: 10 events of Crohn’s disease (CD), four events of
obstruction (two intestinal, two small intestinal), two events of fistula (one anal, one
intestinal) and one event of abdominal mass. 1Fifteen events were reported in 13
patients: eight events of CD, four events of obstruction (two intestinal, two small
intestinal), two events of fistula (one anal, one intestinal), and one event of abdominal
mass. CHARM, Crohn’s Trial of the fully Human Antibody Adalimumab for Remission
Maintenance.
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fistulising disease is of concern, because of the greater risk of
infection at baseline (especially abscesses) for these patients.
15 In
the CHARM fistula cohort, there were no differences in the
rates of adverse events, including infectious adverse events and,
specifically, abscesses, in patients who received placebo com-
pared with those who received adalimumab at either dosage.
This observation is consistent with previous reports.
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CONCLUSIONS
Adalimumab therapy resulted in a significant decrease in the
number of draining fistulas per day compared with placebo.
Significant and complete healing of draining fistulas was observed
in adalimumab-treated patients, and long-term healing of draining
fistulas was maintained over 2 years from the baseline of the
CHARM study. Adalimumab was well tolerated, with a safety
profile consistent with previous studies in patients with CD.
Figure 6 Sample calculation of the mean number of draining fistulas per day. (A) Hypothetical patient 1—minimal disease activity yet not achieving
complete healing* at either week 26 or week 56. (B) Hypothetical patient 2—significant disease activity yet achievement of complete healing* at week
56. *Complete healing, no draining fistulas for at least the last two post-baseline evaluations in the double-blind period.
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ANSWER
From the question on page 896
The computed tomography (CT) scan showed a circumlinear
calcified structure impacted in the small intestine (fig 1 in the
question, arrow). When asked, she recalled having soup of
chopped whole fish body at the previous dinner but was
unaware of ingestion of a fish bone. Laparotomy was performed
because of a high suspicion of perforation by the fish bone. The
laparotomy showed a fish bone, 3.5 cm in length, penetrating
the jejunum without the formation of an abscess (fig 1, below).
The perforation was sutured and the patient had an uneventful
postoperative recovery.
Fish bones are one of the most commonly ingested foreign
bodies and causes of bowel perforation. Because of the low degree
of radio-opacity, fish bones are difficult to detect by plain
radiographs. The absence of free air under the diaphragm is
another difficulty of diagnosis in most cases with fish bone
perforation. Therefore, CT has been the key to diagnosis of
perforationbyanon-metallicforeignbody.Despiteitssuperiority,
lack of observer awareness and thicker CT slices may be the
potential limitations in detecting fish bone perforation.
1 This case
is an important reminder that fish bone perforation should be
included in the differential diagnosis for acute abdomen in
cultures in which unfilleted fish is a culinary delicacy.
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Figure 1 Intraoperative picture of a fish bone perforating the jejunum.
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